Covering: Biology - Neuroscience - MedicineCovering: Biology - Neuroscience - Medicine
All explained papers

Nature Medicine, 2026 Sep 16 · 7 min read

One Injection, No More Needles: Gene Therapy for Hemophilia B Reaches Adolescents

Your blood knows how to stop a bleed. It does this through a chain reaction. One protein wakes up another, which wakes up another, and eventually a clot forms. It happens fast. You get a cut, you bleed for a minute, then you stop.

People with hemophilia B are missing one protein in that chain. It is called factor IX. Without it, the chain breaks down before it finishes. Small cuts are usually fine. But a bleed inside a joint, or deep in a muscle, is a different story. Those can take weeks to heal. And if it keeps happening over years, the joint gets destroyed. Permanently. It looks and feels like severe arthritis, except it happened to someone who may be a teenager.

Living with severe hemophilia B means carrying that awareness all the time. Contact sports are out. A bad fall is not just a bad fall. Even with treatment, life involves a lot of planning around what could go wrong. Some kids grow up avoiding whole categories of activity. Some end up with permanent joint damage from bleeds that happened before they were old enough to be on a regular treatment schedule. The disease starts early and keeps going.

The treatment that has existed for decades is this: you take factor IX produced in a lab and inject it into the bloodstream. The chain works again, the bleed stops. Some patients do this every few days. Every week of their lives, indefinitely.

It works. It keeps most people safe. But it is a lot to manage. And it does not actually fix anything. The liver still cannot make its own factor IX. You are always topping it up from outside.

There has been a lot of work to make the treatment less burdensome. Older versions of factor IX needed to be injected more often. Newer versions stay in the body longer, so some patients go down to weekly injections. There are also newer treatments that work differently, through a different mechanism entirely, that have helped some patients go even longer between doses. These are real improvements.

But none of them change the core situation. The liver cannot make factor IX. The only way to have it is to keep bringing it in from outside. That will be true every week, every year, for life.

The paper published this week in Nature Medicine asks a different question. What if you could teach the liver to make its own?

That is the basic idea behind gene therapy. And it starts with a simple fact about your liver: it already has everything it needs to produce factor IX. The machinery is there. What is missing is the right instructions. In hemophilia B, the gene that carries those instructions is broken.

Gene therapy means delivering a working copy of that gene directly into liver cells. Once the cells have the right instructions, they start making the protein on their own.

The hard part is getting the gene there. You cannot just inject it into someone's arm and expect it to find liver cells. You need a vehicle. Something that can travel through the bloodstream, get specifically into liver cells, and drop off the package.

The vehicle used here is a virus. But not the kind that makes you sick. This one has been stripped down until it is basically just a delivery shell, with no ability to cause infection. It is very good at finding liver cells. Scientists load it with the working copy of the gene, inject it, and it travels to the liver and delivers.

The version of the gene being delivered is not the standard human version. It is a stronger version called factor IX Padua, named after a city in Italy where a patient was found who had unusually good clotting. Researchers traced this back to a variant of factor IX that works about eight or nine times better than normal.

Why use the stronger version? Because delivery is not perfect. Not every liver cell gets the package. If you start with a version of the protein that is much more effective, you still get meaningful results even when only some cells are reached.

Gene therapy for hemophilia is not a brand new idea. Researchers have been working on it for about twenty-five years. The early attempts ran into problems. Some caused immune reactions. Others raised concerns about where exactly in the cell's DNA the delivery vehicle was landing. Progress was slow.

But the last decade changed things. Better delivery vehicles. Better versions of the therapeutic gene. Better understanding of how to dose it. By the early 2020s, adults with hemophilia B were being treated with gene therapy in clinical trials and doing well. Factor IX levels rose dramatically in many patients and stayed up for years. That led to regulatory approvals for adults in several countries.

The next question was whether teenagers could be treated too. That is what this trial was designed to find out.

Now for the trial.

Eleven teenagers were enrolled. Ages twelve to seventeen, all with severe hemophilia B. Their factor IX levels before the trial were at or below two percent of what a typical person has. You need more than fifty percent to clot normally. These kids had almost none.

Before the treatment, they were averaging nearly fourteen bleeds per year. That is more than one a month, even while on regular infusions.

Each of them got one infusion of the gene therapy. One shot.

Twelve months later, their average factor IX level was around forty percent of normal. That is up from almost nothing. At that level, spontaneous bleeds rarely happen.

The bleed count tells the same story. Fourteen per year before. After the treatment, about half a bleed per year across the group on average. Several of the eleven had no bleeds at all during that twelve months.

On safety, some kids had elevated liver enzymes during the follow-up period. That means the liver was reacting to the delivery vehicle. This is a known issue with this type of therapy. It was managed with steroids in some cases and resolved. No serious unexpected problems were reported.

Now let's talk about how this trial was designed, because that matters for how much to trust the results.

There was no control group. No kids who got a placebo injection and were watched alongside the treated group. Instead, each kid was compared against their own history. What was their bleed rate before? What is it now?

That is actually a reasonable way to do this, for a specific reason. These kids had well-documented bleeding histories. They were on regular treatment before the trial. The baseline was not a guess. So comparing their bleed count before and after makes sense.

But there are limits, and they are worth naming.

Eleven is a small number. When you have eleven people in a study and the results look great, it could be that the treatment is great. It could also be a run of luck that would not hold in a bigger group. You cannot tell yet.

There is also something that happens in any study where people know they are being watched. They may be more careful. They may report things differently. They may follow their treatment instructions more closely. Any of those could make the results look better than the treatment alone is responsible for. That does not mean the results are wrong. It means bigger trials are needed to be sure.

There is one more thing specific to treating teenagers. The gene delivery does not become a permanent part of the cell's DNA. It sits as a separate piece inside the cell. When liver cells divide as the body grows, the new cells do not inherit it. The instructions get diluted out over time.

In adults, the liver is mostly done growing. In teenagers, it is still growing. So the factor IX levels that look excellent today may drop as these kids get older. Nobody knows yet how much or how fast, because this trial only covers twelve months. Some patients may need another treatment down the road. Whether that is even possible without the immune system rejecting the same delivery vehicle a second time is an open question.

So what does this mean for a teenager with severe hemophilia B right now?

It means a treatment exists that, in a small trial, turned fourteen bleeds a year into almost none. With one infusion. That is a meaningful change in what daily life looks like.

It does not mean the treatment is ready for everyone. Bigger trials still need to happen. The question of how long the benefit lasts still needs answering. But for a disease where the only option has been constant management with no end in sight, this points somewhere new.

The goal has always been to fix the underlying problem rather than just keep up with it. For decades that goal was theoretical. The biology was understood, but making it work safely in a person was a different matter. This trial is the first time it has been shown to work in teenagers with hemophilia B. One infusion. Fourteen bleeds a year down to almost none.

What comes next is more trials, more patients, and more time to see how long the benefit holds. But the direction is clear, and for the eleven teenagers in this trial, the results were real.

The paper is PMID 42749889, published in Nature Medicine on September 16, 2026. This is based on the published abstract; full text is behind a paywall.